The biotech sector, proxied by the XBI ETF, is trading higher today, continuing a period of strong performance driven by a robust environment for mergers and acquisitions. The recent announcement of Eli Lilly's intention to acquire AtaiBeckley for approximately $2.8 billion reinforces the narrative of large pharmaceutical companies seeking to replenish their pipelines by acquiring smaller, innovative firms. This trend, coupled with a more favorable regulatory environment and a recent increase in biotech IPOs, is boosting investor confidence across the industry.